4CPS-095 Abstract withdrawn

View at publisher Summarise with VIRAT
Authors: A Colicchio, V Lanzetta, D Scarlattei, A Lupoli, M Cosma, I Putaturo, B Mantovani, P Zuccheri
Cited by: 0

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

Background and Importance Cyclin-dependent kinase 4/6 inhibitors (CDKi) are a standard of care for HR+/HER2- breast cancer in combination with an aromatase inhibitor or fulvestrant. The three available CDKi, abemaciclib (Abe), palbociclib (Pal), and ribociclib (Rib) have distinct toxicity profiles that may require therapeutic switches or dose reductions. Aim and Objectives Analysis of therapeutic switches in a cohort of patients treated with CDK4/6 inhibitors to evaluate safety profiles in real-world practice and compare them with available evidence from the literature Material and Methods A retrospective analysis of CDK4/6 inhibitor prescriptions (01/2022–07/2025) was performed using institutional software. Annual patient numbers, therapeutic switches, and related clinical reasons were evaluated. A systematic literature review was also conducted to assess consistency between real-world therapeutic choices and available evidence, using the keywords ‘abemaciclib OR ribociclib OR palbociclib OR CDK4/6 inhibitors’ AND ‘toxicity’ OR ‘adverse effects’ OR ‘safety’ AND ‘breast cancer’ OR ‘breast neoplasms,’ restricted to systematic reviews published in the last 5 years. Results The literature search identified 611 studies. After restriction, 38 systematic reviews (SRs) were retrieved, 10 fully analysed, with two deemed relevant as they included the main RCTs and safety comparisons of CDKi. In our cohort, 485 patients were treated: 213 with Pal, 140 with Abe, and 132 with Rib. Six therapeutic switches due to toxicity were recorded: three from Rib to Pal (G4 transaminitis, muscle spasms), two from Rib to Abe (G4 skin toxicity, nausea and ECG alteration), and one from Abe to Rib (G2 gastrointestinal toxicity). Dose reductions were required in 163 patients (34%). Conclusion and Relevance Our findings are consistent with published evidence. Onesti1 reported higher neutropenia rates with Pal and Rib, and more frequent diarrhoea with Abe. Other common toxicities include fatigue, hepatotoxicity, and rash. In line with Kappel,2 we observed hepatotoxicity-related switching from Rib to Pal and GI-related switching from Abe to Rib, reflecting reported differences in safety profiles. Larger observational studies are warranted to identify additional adverse events not captured in registration trials, with potential implications for daily clinical practice. References and/or Acknowledgements 1. Onesti CE. CDK4/6 inhibitors: toxicity profiles. Breast Care. 2021. 2. Kappel C. Safety of CDK4/6 inhibitors. Cancers. 2023. Conflict of Interest No conflict of interest

Fields of Study & Subjects

Advanced Breast Cancer Therapies Breast Cancer Treatment Studies PARP inhibition in cancer therapy

Publication details

Journal / source
European Journal of Hospital Pharmacy
Pages
A97.1–A97
Publication date
1 March 2026
Language
EN